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IMPLANTS AND DEPOT INJECTIONS FOR TREATING 
OPIOID DEPENDENCE: QUALITATIVE STUDY OF PEOPLE 
WHO USE OR HAVE USED HEROIN 
 
 
ABSTRACT  
 
Background 
Long-acting opioid pharmacotherapy (OPT) is presumed to offer benefits over more 
conventional OPT formulations. This paper analyses the views and experiences of people 
who use or have used heroin in order to explore two novel systems for delivering long-acting 
OPT: implants and depot injections. New materialism theorizing is used to interpret and 
frame the findings.  
 
Methods 
Qualitative data were generated via 7 focus groups conducted during 2017 in London, UK. 
Participants (n=44; 28 men and 16 women; ages 33-66 years) had all received OPT. Focus 
group discussions covered real and potential OPT delivery systems. All participant data 
relating to implants and depot injections were coded using MAXQDA software and analysed 
inductively via Iterative Categorisation.  
 
Findings 
Participants discussed implants and depot injections in terms of interacting physical, 
psychological and social factors: dose stability; OPT administration; stopping treatment; co-
presence of an antagonist; breaking rituals and habits; reduced choice and control; feeling 
normal; information needs; getting on with everyday life; and social interaction. Participants 
identified both benefits and concerns, and variable needs and preferences, with respect to 
each delivery system. 
 
Conclusions 
Implants and depot injections are not ‘fixed’ medications that can be administered to people 
to achieve pre-determined treatment aims. Rather, they are complex ‘assemblages’ with 
uncertain outcomes. Furthermore, they are themselves part of wider interactive 
‘assemblages’. Drug developers and treatment providers need to understand this complexity 
in order to target long-acting OPT at people most likely to benefit from it, and to reduce any 
unintended negative consequences.  
 
KEYWORDS: Qualitative study, opioid pharmacotherapy, opioid dependence, implants, 
depot injections, new materialism. 
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IMPLANTS AND DEPOT INJECTIONS FOR TREATING 
OPIOID DEPENDENCE: QUALITATIVE STUDY OF PEOPLE 
WHO USE OR HAVE USED HEROIN 
 
 
1. INTRODUCTION  
 
 
‘Opioid pharmacotherapy’ (OPT), ‘opioid substitution treatment’ (OST) and ‘opioid agonist 
treatment’ (OAT) are all terms that describe the administration of medications to people 
dependent on opioids in order to achieve ‘defined treatment aims’ (WHO/UNODC/UNAIDS, 
2004). Pharmacotherapies for opioid dependence include opioid agonists (e.g. methadone), 
partial agonists (e.g. buprenorphine), opioid antagonists (e.g. naltrexone), and alaph-2-
adrenergic agonists (e.g. lofexidine) (Stotts et al., 2010). Traditionally, pharmacotherapy has 
tended to be taken daily, in liquid or tablet form, and under close medical supervision. More 
recently, long-acting formulations have become available for clinical practice. For example, 
the United States Food and Drug Administration (FDA) approved the first buprenorphine 
implant (6-month duration) in May 2016 and a first buprenorphine depot injection (monthly 
administration) in November 2017 (Sigmon and Bigelow, 2016). Other products, such as 
naltrexone implants, have been developed and the market is expanding (Comer et al., 2007; 
Hegde et al., 2013; Stotts et al., 2010). 
 
Long-acting OPT is presumed to offer benefits over more conventional OPT formulations. 
By providing sustained medication release, it makes daily dosing unnecessary, so reducing 
the frequency of clinic/pharmacy visits and obviating the need for take-home doses. This is 
expected to improve patient adherence, reduce the treatment burden (for both patients and 
clinicians), and remove the risk of illicit diversion (Sigmon et al., 2006; Sigmon and Bigelow, 
2016). These claims have not, however, been tested to-date. Typically, studies of new 
medicinal products are conducted by natural scientists who assume that medicines have 
inherent physical properties, which cause predictable changes in patients once administered 
(Bundy and Quintero, 2017; Gomart, 2002). Their research, conducted primarily for drug 
development and regulatory purposes, focuses on product characterization, safety and 
efficacy (such as dose, storage requirements, side effects, adverse reactions, 
pharmacokinetics, and metabolism) (DiMasi, 2002; Gad, 2017; Rosenthal et al., 2013).  
 
Social scientists have, meanwhile, argued that medicines and their effects relate to complex 
social and cultural factors that vary across time and place (Gomart, 2002; Barad, 2007). 
Working largely within a social constructivist paradigm, social scientists began to study OPT 
during the 1990s. Their initial research was descriptive and applied, exploring heroin users’ 
views and experiences of methadone, and their reasons and motivations for engaging with 
methadone treatment (Jones et al., 1994; Koester et al., 1999; Murphy and Irwin, 1992; 
Neale, 1998, 1999a, 1999b; Sheridan and Barber, 1996). Later, studies became more 
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theoretical, drawing upon sociological and psychological concepts such as identity, stigma, 
surveillance, and social control (see, for example, Harris and Rhodes, 2013; Monaghan and 
Wincup, 2013; Radcliffe and Parkes, 2013; Strike et al., 2013; Treloar and valentine, 2013).  
 
In recent years, social scientists have also drawn upon the interdisciplinary field of ‘new 
materialism’ to understand methadone and methadone treatment (Fraser and valentine, 2008; 
Gomart, 2002; Keane, 2013; valentine, 2007). New materialism is distinct from biological 
and constructivist approaches to understanding the world in that the physical/natural and the 
social/cultural are considered contiguous rather than distinct. The focus of new materialism is 
on ‘matter’; a generic term used to encompass physical and material things, but also human 
bodies, other animate organisms, and more abstract concepts such as places, spaces, time, and 
practices (Braidotti, 2013; Fox, 2016; Fox and Alldred, 2018; Haraway, 1991). Proponents of 
new materialism maintain that all matter – that is, all human and non-human phenomena – is 
relational and contingent rather than fixed or stable (Barad, 1996; Coole and Frost, 2010; 
Fox, 2016). Matter affects and is affected by other matter, and all matter is produced in 
interacting networks (or ‘assemblages’) of other matter (Deleuze and Guattari, 1988).  
 
Drawing upon new materialism, and particularly actor-network theory (a key strand of new 
materialism), Gomart (2002), valentine (2007) and Fraser and valentine (2008) have all 
argued that methadone, being matter, is neither a stable, pre-existing chemical substance nor 
a social construction. Methadone is simultaneously a physical phenomenon with biochemical 
properties and a deeply social, cultural and political phenomenon. It is multivalent, linked to 
other matter, relational and interactive. Methadone varies from one context to another. It acts 
pharmacologically (producing tangible physiological effects) but only in interaction with 
other human and non-human ‘actants’ (Bundy and Quintero, 2017). In short, methadone’s 
qualities are not inherent in its pharmaceutical properties, but are co-produced within 
complex networks of other matter (Bundy and Quintero, 2017; Latour, 2005; Law, 1999). 
 
In this paper, our focus is neither on methadone nor on any other specific medication. Our 
aim is rather to explore two novel systems for delivering long-acting OPT (implants and 
depot injections), and we do this from the perspective of people who use or have used heroin. 
Our interest follows from the argument that OPT is likely to be more effective if we take 
patients’ views, experiences and motivations into account when making treatment decisions 
(Neale, 1999a; Neale, 2013). In the Discussion, we return to new materialism to help interpret 
and frame our findings.  
 
 
2. METHODS 
 
Data were generated as part of a qualitative focus group (FG) study exploring real and 
imagined OPT delivery systems: liquids, tablets, nasal sprays, implants and depot injections. 
Qualitative methods are frequently used to investigate the acceptability of emergent health 
care interventions, including new medicines. This kind of inquiry can be undertaken using 
interviews or focus groups conducted with people who have not received the intervention 
Article accepted in Drug and Alcohol Dependence Neale et al. (2018) 
 
 6 
under investigation, but who belong to the target patient population or to a closely related 
population. For example, a number of published studies have explored women’s 
hypothesized perceptions of permanent and long-acting contraception, including implants and 
depot injections (Glasier et al., 2008; Harrington et al., 2015; Zimmerman et al., 1990).  
 
In this study, the participants (n=44) were all current or former heroin users (28 men and 16 
women; ages 33-66 years). The groups were conducted in drug and alcohol services, a peer 
support recovery service, and a homeless hostel in London, UK, during March and April 
2017. Ethical approval for the study was granted by the United Kingdom (UK) NHS 
Research Ethics Service. Recruitment of participants occurred in several ways: posters with 
the researchers’ contact details were displayed in the services; researchers approached 
potential participants in person at the services; workers encouraged service users to contact 
the researchers; and participants from the earlier focus groups introduced the study to their 
peers. Everyone who expressed interest in taking part (n=76) completed a basic screening 
questionnaire that covered gender, age, ethnicity, substance use, prescribed medications, and 
contact details. The researchers then used the screening information to identify and invite 
people to the groups.  
 
Groups were organised according to participants’ current treatment status to minimise the 
likelihood of anyone comparing their own treatment with other treatments and then becoming 
dissatisfied. This resulted in 7 groups: oral methadone (FGs 1 and 2); buprenorphine tablets 
(FGs 3 and 4); injectable OPT (FG5); and former OPT (FGs 6 and 7). Participants in FG6 
reported no current opioid use at all whereas participants in FG7 were all current users of 
street opioids. One participant had previously participated in a trial of depot injection 
buprenorphine and several others knew people who had had naltrexone implants. In addition, 
one female participant reported that she had had a contraceptive implant. Others were 
familiar with the concept of receiving contraception or treatment for mental health problems 
via depot injections (see Table 1 for additional participant details). 
 
TABLE 1 
 
Each group was facilitated by two researchers who used a topic guide to structure the 
discussions. The guide initially focused on participants’ personal experiences of OPT before 
exploring their views of receiving treatment for opioid dependence via the different delivery 
systems. No specific medications were mentioned as the objective was to focus attention on 
‘how’ the treatment was delivered rather than the particular drug. Participants were provided 
with a brief verbal description of each delivery system and then asked what they thought 
about it, including what they liked and disliked. The information provided to participants 
about implants and depot injections is shown in Table 2.  
 
TABLE 2 
 
Groups lasted between 41 and 63 minutes and were audio recorded. All participants received 
£10 as a gesture of thanks. Audio recordings were transcribed verbatim and then coded using 
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the qualitative software MAXQDA (version 11). The coding frame comprised deductive 
codes derived from the topic guide and inductive codes emerging from the data. For this 
paper, all coded data relating to implants and depot injections were exported from MAXQDA 
into Microsoft Word documents and then analysed inductively through a process of Iterative 
Categorisation (Neale, 2016).  
 
In the first stage of the analyses, the coded implant and depot injection data were reviewed 
line by line to describe aspects of each delivery system that participants liked and disliked. 
Since similar issues were discussed in relation to both systems, and positive comments were 
often opposites of the negative comments, the analyses were merged and then grouped into 
more inductive categories. These categories (n=10) were subsequently organised under three 
headings: i. physical factors (4 categories); ii. psychological factors (4 categories); and iii. 
social factors (2 categories). We use these categories to structure the findings below. 
Differences between participants’ views of the implants and depot injections, and any 
emergent differences between sub-groups of people receiving OPT, were considered and 
documented as part of the analytical process. 
 
 
3. FINDINGS  
 
 
3.1. Physical factors 
 
 
3.1.1. Dose stability 
 
Many participants liked the idea that implants and depot injections guaranteed a regular dose 
of OPT every day. They argued that this was ‘straightforward’ and would help them to feel 
‘stable’ and ‘on a level’. Moreover, it would offer welcome protection from a range of 
contingencies, such as missed doses (e.g. if someone was unable to attend the pharmacy to 
collect their medication), lost doses (e.g. if someone accidentally spilt medication) and 
presumed harms associated with other OPT formulations (e.g. tooth decay linked to the sugar 
in oral methadone):  
 
“Makes sense to me as it [long-acting OPT] is easy, straightforward. You know where 
you are.” (FG2, male) 
 
In contrast, other participants disliked the concept of a stable daily dose. Some expressed 
concern, particularly in respect of the implant, that they would be ‘stuck’ on the same dose of 
OPT and not able to increase or reduce it as they wanted. Others stated that they were used to 
taking substances (street drugs or OPT) every day in order to feel ‘different’, ‘human’, or 
‘alive’. Therefore, they did not want to feel ‘flat’ or ‘not stoned’ as this would likely be 
‘boring’: 
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“I don’t like the sound of that [depot injection] because it means that you’re on a level 
for the whole month… I used to like getting up in the mornings and taking my 
methadone, knowing that in half an hour I’m going to have that really warm glow 
inside.” (FG6, male) 
 
 
3.1.2. OPT administration  
 
Participants regularly voiced concerns about the process of fitting the implants and to a lesser 
extent the injection of the depot formulation. Worries about the implant included the intrusive 
nature of the surgical insertion process, needing to have multiple implants inserted over time 
which might cause scarring (‘we’ll look like Frankenstein’), and potential for infection:  
 
“You’d be going for surgery, minor surgery, every time you went. I’d be worried 
about infection.” (FG5, female) 
 
Additionally, participants were often apprehensive about having something ‘invasive’ that 
they did not ‘trust’, ‘a little bot’, ‘nanite’ or ‘microchip’ implanted inside them. In terms of 
the depot injection, participants explained that they were worried that the injection would be 
painful or might create a haematoma or that the procedure would be a negative reminder of 
an injecting history that they were trying to forget. Some also said that they disliked or feared 
needles: 
 
“I wouldn’t even go there, not even think about it [depot injection], because I don’t 
like needles.” (FG7, male) 
 
 
3.1.3. Stopping treatment 
 
For many participants, a major disadvantage of the depot injection was that it could not be 
removed from the body once administered: ‘once it’s in, it’s in’. As already reported, some 
participants did not like the idea of being unable to change the dose until it depleted. Others 
feared what might happen to them if they experienced side effects or allergic reactions after 
the medication had been injected. In addition, some worried that depot injections would put 
people at increased risk of opioid overdose or might prevent people from receiving effective 
pain relief should they be involved in an accident: 
 
“You would want to know at the end of the day that you could remove it [depot 
injection]. For instance, if… you had a bad reaction to it.” (FG4, male) 
 
Overall, participants felt that an OPT implant was preferable to a depot injection in terms of 
stopping treatment since the implant could be removed by a professional. Moreover, they 
could even take it out themselves if they were unhappy or had an adverse reaction. 
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Evidencing this, participants spoke of knowing people who had ‘cut out’ naltrexone implants 
with a scalpel or razor blade (‘hacking themselves up’) because they had wanted to use street 
drugs: 
 
“If I suddenly wanted it [implant] out and I was in an irrational state, I’m not going to 
have the wherewithal to think ‘Oh, I’ll wait until the morning…  get the proper doctor 
to do it’.” (FG5, male) 
 
Despite this, participants still voiced concerns that the implant might not be easy to take out, 
particularly if it had ‘moved’, ‘got stuck’, or become ‘difficult to locate’.  
 
 
3.1.4. Co-presence of an antagonist  
 
In assessing long-acting OPT, participants routinely reported that it was important to know 
whether or not the medication contained an antagonist drug to ‘block’ the effects of street 
opioids. Nonetheless, opinions were divided on what was best. Some emphasized that the 
antagonist was beneficial as it would enable them to stop thinking about substances and so 
not use street drugs: 
 
“If it [OPT with antagonist] is going to give me three months away from street drugs, 
then of course I’m going to embrace it.” (FG3, male) 
 
Indeed, according to some, there was no point in having long-acting OPT if it did not contain 
antagonist medication. These participants tended to be those most motivated to achieve 
abstinence. Others, meanwhile, disliked the idea that a ‘blocker’ might be included in the 
formulation, expressing concern that they would not be able to use street opioids on top of the 
medication. Furthermore, they might overdose if they tried. 
 
 
3.2. Psychological factors 
 
 
3.2.1. Breaking rituals and habits 
 
Many participants reported that an important benefit of long-acting OPT (both implants and 
depot injections) was their potential to help people break negative rituals and habits relating 
to collecting and taking daily medications. Participants often observed that daily routines 
relating to prescription drugs were effectively extensions of using street drugs. Moreover, 
they undermined treatment progress by ‘tying them down’: 
 
“A lot of the things that go along with getting a script… are habit-forming in 
themselves. Not just drinking the juice [methadone]. Getting the juice… waking up 
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not feeling human until you do that ritual of drinking... they [daily routines] tie you 
down.” (FG2, female) 
 
According to some participants, not having to take medication daily would be particularly 
valuable for people just starting OPT, since it would prevent them from developing habit-
forming behaviours around treatment in the first place. Others felt that those nearing the end 
of treatment would benefit as long-acting formulations could help to wean them off any 
rituals already established. Notably, however, one participant stated that he did not like the 
idea of implants or depot injections precisely because he would miss the daily rituals of 
taking medication: 
 
“I go to the chemist and I get home, have me tea, have me juice [methadone], and I 
feel it kick in as it were… And I’m so used to that.” (FG2, male) 
 
 
3.2.2. Reduced choice and control 
 
Frequently, participants complained that long-acting OPT (both implants and depot 
injections) would reduce the amount of choice and control they would have over their 
medication and lives more generally. Not being able to change or manage their dosage caused 
many to worry that they would feel ‘powerless’, that they would lose some of their 
autonomy, and that they would be less responsible for themselves. In short, they would 
become a ‘hostage’ to their medication and the implants and depot injections would be ‘in 
control of them’: 
 
“I want to be in control, not some substance under my skin.” (FG4, male) 
 
Participants who were receiving take-home or injectable OPT were especially worried about 
this aspect of long-acting formulations, explaining that they were accustomed to managing 
their own medication by taking it as and when they wanted or needed during the day. Despite 
this, some participants suggested that removing control could be an advantage in respect of 
people who might be tempted to use street opioids. 
 
 
3.2.3. Feeling normal 
 
Across all the focus groups, a frequently reported perceived benefit of both implants and 
depot injections was their ability to help people feel ‘normal’: 
 
“That’s when you will be normal. That is normality. Do you get what I mean? It’s like 
you’re not even a drug addict anymore.” (FG1, female) 
 
Participants gave several interconnected reasons for this. First, implants and depot injections 
were invisible, so nobody would know they were receiving OPT. Second, long-acting 
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formulations removed the constant need to attend drug services, doctor surgeries and 
pharmacies; activities that were in themselves disruptive of feeling ‘normal’, not least as 
participants felt they were always making excuses to hide their disappearances. Third, 
participants stated that having an implant or depot injection would mean that pharmacists 
would no longer be able to treat them ‘differently’ or like ‘an addict’. Women, in particular, 
liked the fact that long-acting formulations were discreet and invisible to other customers in 
the pharmacy and to the outside world in general: 
 
“I think there’s less stigma attached to something that nobody can see. You don’t 
drink it, you don’t take it, you’re just another person, and nobody has to know that 
you’ve got that [implant] under your skin.” (FG2, female) 
 
 
3.2.4. Information needs  
 
Although participants were often familiar with implants and depot injections for 
contraception or mental health problems, they still reported that long-acting formulations 
were a new concept for those receiving OPT. Consequently, their knowledge was often 
limited:  
 
“It’s very novel, especially for people that are drug users… I suppose it’s a new thing 
that people aren’t aware of.” (FG6, male) 
 
Participants had many questions and expressed interest in learning more. For example, they 
wanted to know how the technology worked; whether or not it was reliable; what the likely 
side-effects were; whether it might induce withdrawal symptoms; how they would feel as the 
medication wore down; how long opioids would remain in their body; whether implants 
would dissolve or melt; how implants were removed; whether there would be interactions 
with other medications; how they might receive pain relief if needed; whether they would be 
able to drive a car; what the implications were for overdosing on street drugs; whether they 
could vary the dose; whether the dose could be reversed; and how they would wean 
themselves off treatment. Importantly, the absence of such information generated scepticism 
but also fear: 
 
“Lots of medications interact with each other. So what happens if you get unwell and 
you’re in a hospital and it’s already in you, and you might need some medication that 
interacts with it? It just seems really toxic and scary for me.” (FG6, female) 
 
 
3.3. Social factors 
 
 
3.3.1. Getting on with everyday life  
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According to many participants, having to attend appointments or travel to pharmacies to 
collect their OPT was so burdensome and stressful that it hindered their efforts to ‘get on with 
life’. For example, one man reported that he never visited his visit his family who lived in 
another city as he would be too ‘scared’ about not being able to get his daily buprenorphine 
prescription whilst away. Reflecting this, many participants – particularly those who had been 
attending pharmacies for daily supervised consumption for many years and those wanting to 
reduce or come off their OPT – argued that long-acting OPT had another major benefit. By 
reducing the need to attend services all the time, it would ‘free’ them to do more 
‘constructive things’:  
 
“You know it’s there [depot injection]. It’s good, it’s brilliant, because you can get on 
with your life and stuff. It frees you up.” (FG2, male) 
 
In particular, participants welcomed the fact that long-acting OPT would enable them to carry 
out daily chores, fulfil parenting duties, travel, go on holiday, spend time with family, attend 
college, and secure paid employment: 
 
“You could go to work, yeah, all that stuff… You could go to work, go to college, 
whatever.” (FG3, female) 
 
 
3.3.2. Loss of social interaction 
 
As already documented, many participants emphasized that not having to attend pharmacies 
and services regularly was an important benefit of long-acting OPT. Nonetheless, some – 
mostly those who had more recently started treatment and those who also reported mental 
health problems – stated that they would miss attending services. This was because treatment-
related appointments gave them a reason and motivation to go out and interact with other 
people. In other words, standard OPT offered somewhere to go and something to do. For 
example, one woman who had a diagnosis of bipolar disorder said that she liked going to the 
pharmacy as the journey provided her with structure, daily exercise, and a reason to leave the 
house:  
 
“I like going to the chemist every day… It gets me out the house… I’m bipolar. So if 
I don’t have to go out, I’ll just stay indoors in my pyjamas.” (FG3, female) 
 
Another male participant, who reported depression, explained that the only time he left home 
was to go to the pharmacy and he looked forward to this each morning as it was his only 
social interaction:   
 
“Going to the chemist on a daily basis actually gets me outside the house. Because I 
don’t go outside, I really don’t do anything. I’m clinically depressed… That would be 
it, 24 hours a day inside. I wouldn’t be going out and talking to anyone.” (FG2, male) 
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4. DISCUSSION  
 
Our research has explored implants and depot injections for treating opioid dependence from 
the perspective of people who use or have used heroin. This has helped us to understand how 
these new delivery systems will likely be received by patients as they become more widely 
available for OPT. Participants agreed that both delivery systems offered benefits. For 
example, they were discrete and could therefore reduce the stigma that people often 
experience as OPT clients (particularly when collecting medication from pharmacy services). 
Not having to constantly attend services and appointments could also free patients to pursue 
other activities and begin to live ‘normal’ lives (c.f. Nettleton et al., 2013).  
 
Despite these benefits, participants worried about the fitting of the implants, the injecting of 
the depot formulations, having foreign matter inside them, and being unable to control the 
medication dose or stop treatment once started. Participants also often disagreed about 
particular features of long-acting OPT. Thus, some welcomed having a stable daily dose or 
less contact with treatment services whereas others emphasized that they would miss the 
variable sensations associated with oral methadone’s shorter duration of action or would be 
socially isolated if they did not have their daily trip to the pharmacy.  
 
Participants’ accounts illustrated how needs, preferences and perceptions of long-acting OPT 
varied depending on patient characteristics and circumstances, including gender, co-
morbidity, and whether or not someone was new to treatment or motivated to achieve 
abstinence (see also Hatcher et al., 2018). These findings are consistent with the social 
science literature on OPT, and particularly Fraser and valentine’s observation that methadone 
is multivalent (Fraser and valentine, 2008). Long-acting OPT delivered by implants and depot 
injections are similarly not ‘fixed’ medications that can be administered to achieve pre-
determined treatment aims (WHO/UNODC/UNAIDS, 2004). They are complex webs of 
physical, psychological and social factors with uncertain outcomes.    
 
Long-acting OPT can thus be usefully considered as an ‘assemblage’. It may comprise an 
implant or depot injection, but also a dose, with a particular duration of action, with or 
without an antagonist. Moreover, it is fitted in a certain way, is manufactured to disperse 
medication in a particular manner, and might function reliably or not. Additionally, implants 
and depot injections are themselves part of wider ‘assemblages’. Accordingly, they might be 
contraindicated by other medications, they are understood via information sources (or lack of 
them), and they are judged by their interactions with ability to drive, risk of overdose, 
feelings of control, daily rituals and habits, patient/ professional interactions, wider social and 
familial relationships, ability to travel, and employment opportunities etc.  
 
Participants in our study clearly recognized the capacity of long-acting OPT to ‘act’. On the 
one hand, implants and depot injections could invade, hurt or infect their bodies, move 
around or ‘get stuck’, induce memories of an injecting past, control them, and generate fear. 
On the other, they had the potential to help people break rituals and habits, feel ‘normal’, and 
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‘get on with life’. Importantly, however, our participants did not presume that implants and 
depot injections were fixed or immutable phenomena. Consistent with the principles of new 
materialism, these new delivery systems were variable entities that could be affected by other 
matter. Most obviously, long-acting OPT could be countered by the consumption of street 
drugs, implants could be removed under medical supervision or by patients themselves, and 
concerns about toxicity and safety might be mitigated by better information.  
 
 
4.1. Limitations and strengths 
 
Our findings are subject to the same limitations as any qualitative study, including small 
sample size and consequent poor empirical generalizability (Neale et al., 2005; Neale et al., 
2013). In addition, our findings could have been categorized and presented under different 
headings given the overlap between the issues discussed. Despite this, our study is the first 
in-depth qualitative exploration of implant and depot formulations of OPT from the 
perspective of people who use or have used heroin. Our sampling was inclusive of current 
and former heroin users and a range of treatment (and out-of-treatment) groups. We 
additionally established parallels with previous empirical and theoretical work on other OPT 
formulations, particularly methadone. Taken together, this provides support for the 
transferability of our findings to other contexts and settings (Lincoln and Guba, 1985).  
 
 
5. CONCLUSIONS 
 
New OPT formulations as delivered by implants and depot injections seem no more likely to 
be silver bullets for opioid dependence than methadone (Paxton et al., 1978). Moreover, the 
need for qualitative research that provides insights into the views, experiences and 
motivations of those for whom OPT is intended remains as important now as it ever was. We 
suggest that patients will view and engage with implants and depot injections in complex 
ways depending on interacting physical, psychological and social factors. Both drug 
developers and treatment providers need to understand this complexity in order to increase 
the likelihood that long-acting OPT is targeted at people most likely to benefit from it, but 
also to reduce the risk of unintended negative consequences (e.g. self-removal of implants, 
patients feeling disempowered, premature loss of contact with professionals, and overdose).  
 
To conclude, we suggest that developers of implants and depot injections should actively 
seek to build flexibility and choice into their products, particularly in relation to dosage, 
duration of action and partial agonist/antagonist combinations. Given heroin users’ concerns 
about the irreversibility of long-acting OPT, options for smaller dosages and shorter durations 
of action that can be increased incrementally could be beneficial. Crucially, there also seems 
to be a need for accessible information to help potential patients understand, and make 
informed decisions about, these new products. The content and format of this information 
could be developed with heroin users to ensure that it addresses their questions and uses 
appropriate media and language. Prescribers similarly need to provide potential patients with 
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verbal information, and afford them sufficient opportunity to ask questions and discuss 
concerns before commencing any long-acting treatment. Since some heroin users are likely to 
be anxious about losing the professional contact associated with daily dosing, the need for - 
and availability of – replacement psycho-social support should likewise be carefully 
considered.  
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Table 1: Participant details  
Demographic 
characteristics 
FG a 1 
Oral 
methadone 
(n=4) 
FG2 
Oral 
methadone 
(n=8) 
FG3 
Buprenorph-
ine tablets 
(n=8) 
FG4 
Buprenorph-
ine tablets 
(n=8) 
FG5 
Injectable 
OPTb 
(n=6) 
FG6 
Former OPT: 
no current 
street opioids 
(n=6) 
FG7 
Former OPT: 
current street 
opioid use 
(n=4) 
All 
(n=44) 
Gender         
Male 2 (50%) 5 (63%) 6 (75%) 5 (63%) 4 (67%) 4 (67%) 2 (50%) 28 (64%) 
Female 2 (50%) 3 (38%) 2 (25%) 3 (38%) 2 (33%) 2 (33%) 2 (50%) 16 (36%) 
         
Ethnicity         
White /White Britishc 2 4 6 6 5 4 2 29 (66%) 
Asian /Asian British 0 0 0 0 0 0 0 0 (0%) 
Black /Black British 2 2 1 0 0 2 1 8 (18%) 
Mixed or Multiple 0 1 1 1 0 0 0 3 (8%) 
Other 0 1 0 1 1 0 1 4 (8%) 
         
Age         
Mean age (years) 
(range) 
49 
(42-59) 
51 
(43-58) 
46 
(33-55) 
40 
(34-47) 
56 
(47-66) 
47 
(39-58) 
45 
(35-53) 
48 
(33-66) 
         
Street opioid use         
Mean age of first use 
(range) 
23 
(16-33) 
18 
(14-22) 
24 
(14-31) 
23 
(14-35) 
18 
(15-27) 
22 
(15-32) 
23 
(18-26) 
22 
(14-35) 
Mean duration of use  
(range)  
26 
(22-30) 
33 
(25-39) 
22 
(2-37) 
17 
(0-33) 
39 
(27-50) 
n/a 22 
(9-31) 
26 
(0-50) 
Current street opioid use  4 (100%) 6 (75%) 4 (50%) 2 (25%) 2 (33%) n/a 4 (100%) 22 (53%) 
         
Current treatmentd         
None 0 0 0 0 0 6 4 10 (23%) 
Buprenorphine (tablets) 0 0 8 8 0 0 0 16 (36%) 
Methadone (oral) 4 8 0 0 2 0 0 14 (32%) 
Methadone (injection) 0 0 0 0 2 0 0 2 (5%) 
Diamorphine (injection) 0 0 0 0 4 0 0 4 (9%) 
a Focus group; b Opioid agonist treatment; c 21 participants identified as ‘British’, 4 as ‘Italian’, 3 as ‘Irish’, and 1 as ‘European’; d 2 participants were prescribed a 
combination of opioid medications (injectable + oral). The denominator used for the calculation of percentages across all subjects was n=44. Because two subjects from FG5 
were included in the percentages for ‘Current treatment’ twice, the total percentage across all 44 subjects adds up to 105%.  
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Table 2: Information provided to participants about implants and depot injections  
 
• AN IMPLANT is a pellet which gets inserted under the skin. Following a local 
anesthetic, a small cut is made to the skin, and the implant is slipped into the tissue 
under the skin. Once in place, it slowly releases the medication over the course of 
several months. 
 
• A DEPOT INJECTION is given by a doctor or a nurse, usually into the muscle. The 
injection slowly releases the medication which potentially lasts a month or two. 
 
 
 
 
